EM2406H "Cardiovascular Disease Prevention Among PWH in 2024: Lessons from the REPRIEVE Trial" (IM GR-062824)

Purpose and Overview

Purpose and Overview: The purpose of this lecture is to outline the specific presentation mechanisms and treatment strategies to prevent cardiovascular disease among PWH in 2024. Lessons learned from the REPRIEVE trial now form the basis of recent AHA/ACC/DHHS recommendations, which will be discussed in detail.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • 1. What is the main cause of cardiovascular disease (CVD) in people with HIV (PWH)?
  • 2. Know the rationale of the REPRIEVE Trial, REPRIEVE’s primary findings and their impact for the care of PWH globally
  • 3. Appreciate the unique phenotype of CVD in PWH, novel mechanisms of CVD, and the effects of statins on plaque and key biomarkers
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
Course expires: 

Photo: First Last, M.D.Steven Grinspoon M.D.
Professor of Medicine
Division of Nutrition
Harvard Medical School

Available Credit

  • 1.00 AMA


Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome